Bone marrow derived-mesenchymal stem cells downregulate IL17A dependent IL6/STAT3 signaling pathway in CCl4-induced rat liver fibrosis

Shimaa Farouk1*, Salwa Sabet2*, Fatma A. Abu Zahra3, Akmal A. El-Ghor2

1 Department of Biology and Biotechnologies, Faculty of Science & Technology, AL-Neelain University, Khartoum, Sudan, 2 Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt, 3 Medical Research Center, Faculty of Medicine, Ain Shams University, Cairo, Egypt

* These authors contributed equally to this work.
* salwa@sci.cu.edu.eg

Abstract

Therapeutic potential of bone marrow-mesenchymal stem cells (BM-MSCs) has been reported in several animal models of liver fibrosis. Interleukin (IL) 17A, IL6 and Stat3 have been described to play crucial roles in chronic liver injury. However, the modulatory effect of MSCs on these markers was controversial in different diseases. BM-MSCs might activate the IL6/STAT3 signaling pathway and promote cell invasion in hepatocellular carcinoma, but the immunomodulatory role of BM-MSCs on IL17A/IL6/STAT3 was not fully elucidated in liver fibrosis. In the present study, we evaluated the capacity of the BM-MSCs in the modulation of cytokines milieu and signal transducers, based on unique inflammatory genes Il17a and Il17f and their receptors Il17rc and their effect on the IL6/STAT3 pathway in CCl4-induced liver fibrosis in rats. A single dose of BM-MSCs was administered to the group with induced liver fibrosis, and the genes and proteins of interest were evaluated along six weeks after treatment. Our results showed a significant downregulation of Il17a, Il17ra, il17f and Il17rc genes. In accordance, BM-MSCs administration declined IL17, IL2 and IL6 serum proteins and downregulated IL17A and IL17RA proteins in liver tissue. Interestingly, BM-MSCs downregulated both Stat3 mRNA expression and p-STAT3, while Stat5a gene was downregulated and p-STAT5 protein was elevated. Also P-SMAD3 and TGFβR2 proteins were downregulated in response to BM-MSCs treatment. Collectively, we suggest that BM-MSCs might play an immunomodulatory role in the treatment of liver fibrosis through downregulation of IL17A affecting IL6/STAT3 signaling pathway.

Introduction

Liver fibrosis represents the final common pathway of virtually all chronic liver diseases including viral hepatitis, alcohol or drug abuse and metabolic diseases [1], and thus represents the first step toward a number of often mortal complications of liver disease. An effective
treatment for liver fibrosis, aside from liver transplantation, has not been established yet [2]. Therefore, alternative treatments have been considered such as stem cells transplantation as these cells have the ability of self-renewal and differentiation [3].

Mesenchymal stem cells (MSCs) are multipotent adult stem cells that have the ability to differentiate into hepatocyte like cells [4, 5], and have the capacity to secrete a series of cytokines and signaling molecules [6, 7] which can regulate inflammatory responses, stimulate hepatocyte proliferation, and maintain hepatocyte function [8]. In a mouse model of liver failure, the systemic injection of bone marrow or bone marrow-derived MSCs (BM-MSCs) into mice have rescued the disease phenotype [9, 10]. Moreover, anti-fibrotic activities of MSCs have been reported in fibrotic animal models [11, 12].

Several studies have referred to interleukin 17A (IL17A) as a critical key player in liver fibrosis [13, 14]. In different cell types of liver, including hepatic stellate cells (HSCs), IL17 receptors complex IL17RA/IL17RC induce signals that activate intracellular factors such as signal transducer and activator of transcription3 (STAT3) which lead to inflammation and liver fibrosis progression [15, 16]. Activation of STAT3 has been detected in all rodent models of liver injury [17, 18]. Inhibition of the STAT3 pathway in HSCs induces apoptosis [19] and renders cells less susceptible to fibrosis [16, 20]. Interleukin 6 (IL6) stimulates the activation of STAT3 and increases collagen mRNA expression in HSCs, thus accelerating liver fibrosis via Stat3 phosphorylation that in turn activates transforming growth factor beta (TGFβ) signaling cascade through SMAD3 activation [21]. TGFβ when binds to type II TGFβ receptor (TGFβR2), influences activation of Smads dependent pathway [22]. SMAD3 is the predominant mediator of fibrogenic TGFβ downstream signaling and main mediator of fibrogenic response in HSCs [23, 24]. However, the role of STAT3 pathway in liver fibrogenesis appears to be controversial due to the recorded hepatoprotective and proliferative functions of STAT3 [25, 26].

The immunosuppressive effects of MSCs on the inflammation that is associated with hepatic fibrosis are mainly due to MSC-derived secretomes. Hence, MSC-derived soluble factors promote development of anti-inflammatory T-regulatory cells (Tregs) and reduce influx of inflammatory Th17 cells in the inflamed liver [27, 28]. Inhibition of inflammation is one of the therapeutic approaches of liver fibrosis. The IL17A/STAT3 pathway is critical in liver fibrosis [29]. Although the effect of BM-MSCs on IL6/STAT3 pathway was conducted in cancer and has shown that MSCs could promote progression of cancer through activation of IL6/STAT3 pathway [30], the immunomodulatory role of BM-MSCs on IL17A/IL6/STAT3 was not fully elucidated in liver fibrosis. Thus, we investigated the effect of BM-MSCs on IL17A dependent IL6/STAT3 pathway.

Methods

Isolation, purification and characterization of bone marrow-derived mesenchymal stem cells (BM-MSCs)

BM-MSCs were prepared from the tibia and femurs of rats as previously described [31]. Whole Bone-Marrow (100±20g) was flushed with Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% bovine serum (Gibco-BRL, Grand Island, NY, USA). According to the manufacturer’s instructions of the Ficoll density gradient media (Biochrom, Berlin, Germany), nucleated cells were isolated and resuspended in a complete culture medium supplemented with 1% penicillin-streptomycin (Gibco-BRL, Grand Island, NY, USA) and then were incubated at 37°C in 5% humidified CO₂ for 12–14 days. When cultures approached 80% confluence, they were washed twice with phosphate buffer saline (PBS) and were trypsinized with 0.25% trypsin in 1 mM EDTA (Gibco-BRL, Grand Island, NY, USA) for
45 min at 37˚C under shaking. Cells were centrifuged then resuspended in serum supplemented medium and incubated in 50 cm² culture flask and the submitted cultures were claimed as first-passage cultures. Cells were serially subcultured to passage four and cells at passage three (P3) were stained for 30 min with FITC-conjugated anti-rat CD29, PE-conjugated anti-rat CD90 and PE-conjugated anti-rat CD34 antibodies (Beckman Coulter, Brea, CA, USA). Cell analysis was performed using CYTOMICS FC 500 Flow Cytometer (Beckman Coulter, Brea, CA, USA) and analyzed using CXP Software version 2.2.

Labeling of MSCs with PKH26
MSCs were collected during the 4th passage and labeled with PKH26 Red Fluorescent Cell Linker kit (Sigma-Aldrich, Saint Louis, Missouri, USA), according to the manufacturer’s instructions. Labeled MSCs were intravenously injected into the tail vein of fifteen rats. Rats were dissected and Liver tissues were examined with a fluorescence microscope to detect and trace the labeled stem cells.

Animals, CCl₄ induction and treatment with BM-MSCs
Thirty male Sprague-Dawley (SD), 6-week-old and specific-pathogen-free rats weighing each 200–230 g, were purchased from Theodor Bilharz Research Institute (Cairo, Egypt) and were housed at Animal Care Center, Cairo University, with an air-condition (22 ±1˚C, 55% humidity, and 12:12 hrs daylight/darkness cycles), and a free access to standard laboratory feed and water, according to the study protocol. The study protocol was approved by the Institutional Animal Care and Use Committee (IACUC), Faculty of Science, Cairo University, Egypt. All experimental procedures were carried out in accordance with international guidelines for care and use of laboratory animals.

Rats were randomly divided into six groups with five rats per group. Five rats were considered as the normal control group. Liver fibrosis was induced by intraperitoneally (i.p.) injecting 23 rats with CCl₄ (1 ml/kg; Sigma-Aldrich, Saint Louis, Missouri, USA) dissolved in paraffin oil, twice a week for 6 weeks (12 doses) [32]. vehicle control rats (n = 5) were injected with an equal volume of paraffin oil alone. 5 rats from the fibrosis group (fibrosis control group), and all rats from normal control groups were euthanized immediately after the last dose (12th dose) of CCl₄ administration. In the remaining 15 rats of the liver fibrosis group, BM-MSCs (3x10⁶ cells) were injected via the tail vein after 24 hrs of the last dose of CCl₄ (12th dose). The animals in the treated group were sacrificed at 2, 4, and 6 weeks post-transplantation.

In parallel with the treated group, three CCl₄-induced rats were injected with saline instead of BM-MSCs, as a recovery group (R-6W) for six weeks later and sacrificed by the end of the study.

Histopathology and Sirius Red stain
To investigate liver damage in CCl₄ and in CCl₄/MSCs treated rats, a part of the liver tissue was fixed in 10% formyl saline, then embedded in paraffin blocks. Tissue sections (4 μm thick) were stained with hematoxylin and eosin (H&E) for examination by a pathologist as previously described [33].

Sirius Red stain was applied to assess collagen deposition, nuclei were stained with hematoxylin (Sigma-Aldrich, Saint Louis, Missouri, USA), then Picro-Sirius Red stain as per the manufacturer’s instructions (Direct Red 80, Sigma-Aldrich, Saint Louis, Missouri, USA).
Biochemical analysis of liver functions

Alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) were measured to assess liver function using commercially available kits (Biomed Diagnostic, Badr city, Egypt) according to manufacturer’s instructions.

Quantitative real-time reverse transcription polymerase chain reaction (RT-qPCR)

RNA was extracted from liver tissue using RNeasy Mini Kit (Qiagen, Hilden, Germany) according to manufacturer’s instructions. One μg of total RNA was converted into cDNA using cDNA synthesis kit (Qiagen, Hilden, Germany) as per the instructions manual. RT-qPCR was performed according to the instructions of QuantiFast SYBR Green PCR Kit’s manual (Qiagen, Hilden, Germany) to amplify collagen1α1 (Col1a1), α-fetoprotein (Afp), Albumin (Alb), Il17a, Il17ra, Il17f, Il17rc and Stat3 genes. All primers’ sequences (Invitrogen, Carlsbad, CA, USA) are mentioned in Table 1.

Real-time PCR was performed using StepOnePlus system (Applied Biosystems, Foster city, CA, USA) and PCR was carried out in 25 μl reaction volume and reaction conditions for amplification of target genes were as follows: initial denaturation at 95˚C for 10 min followed by 40 cycles of denaturation at 95˚C for 15 s, annealing at 56–60˚C for 30 s, and extension at 60˚C for 30 s. A melting-curve was performed from 60˚C to 95˚C reading every 0.3˚C with 1s hold between reads. Samples were performed in duplicates and the expression of mRNA was normalized to Gapdh gene as endogenous control and the relative fold difference in expression was calculated using ΔΔCt.

Immunohistochemistry

Immunohistochemical examination of IL17A and IL17RA was performed using 5 μm paraffin sections. Sections were deparaffinized in xylene and rehydrated in alcohol and distilled water. Retrieval of antigens was performed by heating sections in solution (10 mM citrate buffer, pH 6.0) in a pressure cooker, 3% H2O2 was used to eliminate endogenous peroxidase. Slides were washed with TBS–Triton three times and one time with TBS for 5 min. Nonspecific binding was blocked using 5% goat serum for 30 min and the blocking buffer was then removed and sections were incubated with a polyclonal anti–IL17A antibody (1:2000) (USBiological, Salem, MA, USA), polyclonal anti–IL17RA antibody (2.5 μg/ml) (GeneTex, Irvine, CA, USA) and polyclonal antibody to PCNA (2.5mg/ml) (ThermoFisher Scientific, Rockford, IL, USA). Negative control samples were incubated with rabbit serum replacing first antibody.

Table 1. Sequence of primers used in RT-qPCR analysis.

| Gene   | Forward primer | Reverse primer | Accession Number |
|--------|----------------|----------------|------------------|
| Il17a  | CCGAGATAACTTTGAGGCTATA | AAGGATTTTGACTTCACA | NM001106897.1 |
| Il17f  | GAAAAGCCTCTTTGATCCC | ACGGAGCTCAAGGATGTTG | NM001015011.2 |
| Il17ra | GGTTGTATGGCTCTACAC  | ACAGGCAATGACTGAGAAC | NM001078832.2 |
| Il17rc | GACCTCAGAACATTACTTTAAAACCACACT | GCCQAAGTGGTGCTCTAACAGA | NM001170565.1 |
| Col1a1 | GTGGCGATGCGGCTGCTGTAC | CCTAGACTCGCTGCCTGTGTGAC | NM053304.1 |
| Alb    | GATGGGCTGAAAGAGAACCC | GTGAGCAGCCTCTGTTG | NM134326.2 |
| Afp    | TCTGGACGCGTCCTGGGCTG | AATGGTAAAGGCGGATGCCTGGT | NM012493.2 |
| Stat3  | CACCCCTGAAGCTGGCCAC | TATGCTGCGGGTGCTGGT | NM012747.2 |
| Stat5a | GCCCTCAGGCTCCTCAAC | AAAAGCGGCGGCTGACT | NM017064.1 |
| Gapdh  | GTATCGGAGCGGCTGGTAC | CTTGCGCTGGTGAGCTAC | NM017008.4 |

https://doi.org/10.1371/journal.pone.0206130.t001
incubation overnight at 4°C and washing, the sections were incubated with biotinylated goat anti-rabbit IgG antibody. After washing, peroxidase-coupled antibody was applied for 30 min at room temperature. Bounded antibodies were detected via 3, 3'-diaminobenzidine tetrachloride (Sigma-Aldrich, Saint Louis, Missouri, USA). All sections were then counterstained with hematoxylin. Brown-yellow staining was recognized as positive in the cells.

**Western blot assays**

The levels of p-STAT3, p-STAT5, p-SMAD3, and TGFβR2 proteins were assessed in liver tissue as previously described [34]. The liver tissue was homogenized in RIPA buffer containing protease and phosphatase inhibitor cocktail (BioBasic, Ontario, Canada). The total protein levels were quantified using the Biorad assay, 20–30 μg of total protein from the cell lysate were fractionated by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to a polyvinylidene difluoride (PVDF) membrane (Bio-Rad, Hercules, CA, USA). Membranes were blotted overnight at 4°C with the primary antibodies, anti p-STAT3, anti p-STAT5, anti p-SMAD3 or anti TGFβR2 (ThermoFisher Scientific, Rockford, IL, USA) at concentration (1:1000), and then incubated with the horseradish peroxidase (HRP)-conjugated secondary antibodies against rabbit IgG (ThermoFisher Scientific, Rockford, IL, USA) for 1 hr at room temperature. β-actin was used as loading control. Band intensity was analyzed by ChemiDoc imaging system with Image Lab software version 5.1 (Bio-Rad Laboratories Inc., Hercules, CA, USA).

**Estimation of IL2, IL6 and IL17A protein levels by ELISA**

The serum levels of IL17A (Invitrogen, Carls, CA, USA), IL6 and IL2 (KomaBiotech, Seoul, Korea) were measured according to manufacturer’s instructions.

**Statistical analysis**

Results were analyzed using statistical package for the social sciences software (SPSS, Chicago, IL, USA), version 24 & 25. Data were expressed as mean ± SD. Comparisons between groups were assessed using analysis of variance (ANOVA) with multiple comparisons post hoc test. P-value less than 0.05 was considered statistically significant.

**Results**

**MSCs culture detection and homing**

Successful MSCs were confirmed by their morphology under microscope (Fig 1a) and flow cytometric analysis showed that the surface markers were positive for CD29 and CD90 and negative for CD34 (Fig 1b). After intravenous injection of labeled stem cells in the tail vein of the rats, BM-MSCs were detected in paraffin sections of liver tissue by fluorescent microscope in the treated groups (Fig 1c and 1d).

**BM-MSCs ameliorate liver fibrosis in CCl4-induced rats**

Serum levels of ALT, AST and ALP are considered as sensitive indicators of liver damage and hepatic function [35]. Therefore, ALT, AST and ALP levels were assessed by colorimetric and kinetic methods and were significantly increased \((P<0.05)\) in CCl4 group by 4, 3 and 2.5 folds, respectively, compared to control groups, while they were significantly decreased \((P<0.05)\) after treatment with BM-MSCs (Table 2).

The assessment of collagen deposition was provided by Sirius-red stain (Fig 2a), a significant reduction of fibrosis \((P<0.05)\) was noticed \((5.24\pm1.14\%, 3.22\pm0.98\%, \text{and } 1.65\pm0.21\%)\) at
the 2\textsuperscript{nd}, 4\textsuperscript{th} and 6\textsuperscript{th} weeks, respectively) compared to CCl\textsubscript{4} group (8.82±1.68\%) and normal group (0.68±0.21\%) as well as oil control group (0.78±0.32\%) (Fig 2b). Also, no significant association was detected ($P > 0.05$) between recovery group (8.82±1.68\%) and CCl\textsubscript{4} group (7.9±0.36\%) (Fig 2c).

These results were in accordance with the improvement of histopathological characteristics of fibrotic liver tissue (Fig 3).
Liver regeneration

Enhancement of liver regeneration after transplantation was assessed by measuring PCNA protein expression in the liver tissue (Fig 4a). The 6th week BM-MCs treated group (T-6W) have shown significant elevation of PCNA protein ($P > 0.05$) compared to CCl$_4$ model group and no significant difference ($P > 0.05$) was detected in CCl$_4$ compared to the recovery group (R-6W) (Fig 4b).

As noted earlier, the expression of COL1A1, AFP and ALB are correlated with progression of liver fibrosis [36, 37]. Thus, we assessed the mRNA expression of Col1a1 and it was significantly upregulated ($P < 0.05$) by 7.48 folds in CCl$_4$ model group compared to control group, administration of BM-MSCs revealed a significant downregulation of Col1a1 ($P < 0.05$) at the end the 2nd, 4th and 6th weeks by 4.9, 5.64 and 7.08 folds, respectively (Fig 5a). CCl$_4$-induced group exhibited low Alb gene expression which decreased by 0.71 fold compared to both control groups. In response to BM-MSCs administration, Alb expression was significantly increased ($P < 0.05$) in the second, fourth and sixth week groups compared to CCl$_4$ group by 7.41, 8.32 and 8.32 folds, respectively (Fig 5b). Moreover, AFP gene expression significantly increased ($P < 0.05$) by 1.84 folds in CCl$_4$ model compared to the normal diet and paraffin control groups, while following stem cell administration, the expression was significantly reduced ($P < 0.05$) by 0.54,1.08 and 1.99 folds at the end of the 2nd, 4th and 6th weeks, respectively (Fig 5c).

Table 2. Estimation of liver functions.

|                  | Normal control | Paraffin/oil control | CCl$_4$ | CCl$_4$+BM-MSCs (2w) | CCl$_4$+BM-MSCs (4w) | CCl$_4$+BM-MSCs (6w) |
|------------------|----------------|----------------------|---------|----------------------|----------------------|----------------------|
| ALT (u/l)        | 16.00±3.16     | 16.40±3.36           | 78.60±15.01 | 35.00±4.30           | 33.00±10.93          | 26.80±6.69           |
| AST (u/l)        | 11.80±1.79     | 13.20±2.59           | 45.60±12.66 | 32.80±3.42           | 29.20±10.66          | 23.00±6.52           |
| ALP (u/l)        | 128.20±7.40    | 128.00±11.25         | 317.20±30.65 | 224.40±17.16         | 198.80±27.65         | 175.20±29.54         |

Data were expressed as mean ± SD.

https://doi.org/10.1371/journal.pone.0206130.t002
BM-MSCs administration downregulated the expression of IL17A, IL17RA and affected the downstream IL6/STAT3 signaling pathway

The critical role of IL-17A signaling in the pathogenesis of liver fibrosis was previously suggested [16, 38]. In the same context, our results showed that mRNA expression of Il17a, Il17ra, Il17rc and Il17f were significantly overexpressed (P < 0.05) by 12.81, 4.2, 2.08 and 1.5 folds, respectively in CCl4 model group compared to control groups (Fig 6a–6d). BM-MSCs administration ameliorated the expression of Il17a by 1.32, 3.8 and 9.99 folds at the end of the 2nd, 4th and 6th weeks, respectively, with a significant reduction (P < 0.05) observed only by week six of administration compared to CCl4 group (Fig 6a). Il17f gene was downregulated by 0.62 fold in 2nd week and reduced significantly (P < 0.05) by 1.02 and 1.19 folds at the end of the 4th and 6th weeks, respectively, compared to the CCl4 model (Fig 6b). The expression of Il17ra mRNA was significantly downregulated (P < 0.05) compared to CCl4 group by 1.81, 1.87 and...
Fig 5. Gene expression of Alb, Afp and Col1a1 in liver tissue. The relative quantification of a. Col1a1, b. Alb, and c. Afp were carried out utilizing the $2^{-\Delta\Delta C_T}$ ± standard deviation (SD) method and Gapdh gene expression as housekeeping gene. Each experiment was performed in duplicate and results are expressed as fold induction of mRNA expression ($n = 5$). *P<0.05, #P<0.05 compared to control groups.

https://doi.org/10.1371/journal.pone.0206130.g005
3.32 folds at the 2nd, 4th, and 6th weeks, respectively (Fig 6c). Il17rc gene expression was significantly reduced ($P < 0.05$) after BM-MSCs treatment by 0.95, 1.34 and 1.49 folds at the end of the 2nd, 4th, and 6th weeks, respectively (Fig 6d).

Similar results were observed at the protein level, where IL17A protein was almost absent in normal and paraffin oil control groups of liver tissue while the tissue derived from CCl4-induced fibrosis group and recovery group showed high degree of expression of IL-17A and IL17RA proteins. After MSCs transplantation, the tissue exhibited a gradual decrease of the expressed IL17A and IL17RA proteins in accordance with the times of treated groups (Fig 7). Immunoreactivity was localized intracellularly in the hepatocytes surrounding the central vein portal area.

Noticeably, one of the Stat3 signaling cytokine with pro-fibrogenic properties is IL17A, enhancing activation of hepatic myofibroblasts either directly or through IL6 secretion [16, 39] and collected evidences indicate the contribution of activated STAT3 in liver fibrosis [18]. Thus, we assessed the expression levels of STAT3 and our CCl4 model group revealed that Stat3 mRNA was significantly overexpressed ($P < 0.05$) by 9.45 folds compared to control groups. Stat3 mRNA was significantly ($P < 0.05$) reduced by 2.85, 2.9 and 2.9 folds after the 2nd, 4th and 6th weeks, respectively, after treatment with BM-MSCs (Fig 8a). We analyzed p-STAT3 levels in both control groups, CCl4 group and BM-MSCs treated groups. Phosphorylated STAT3 levels were significantly ($P < 0.05$) upregulated in the CCl4 group compared to both controls, while significant ($P < 0.05$) reduction of p-STAT3 was observed after week six of BM-MSCs administration (Fig 8c and 8e). No significant difference in of p-STAT3 expression was noticed between CCl4 and recovery groups ($P > 0.05$) (Fig 8f).
The molecular consequences of p-SMAD3 and TGFβR2 proteins and development of liver fibrosis were demonstrated that Stat3 is essential to collaborate with SMAD3 mediating TGFβ induced fibrotic response in hepatic stellate cells [40]. In correlation with our data, p-SMAD3 (Fig 9a and 9c), and TGFβR2 (Fig 9b and 9c) proteins significantly increased ($P < 0.05$) in the fibrosis group compared to controls, and they were significantly downregulated ($P < 0.05$) from the 2nd week of BM-MSCs treatment. On the other hand, CCl4 and recovery group showed no significant difference ($P > 0.05$) in expression of p-SMAD3 and TGFβR2 (Fig 9d and 9e).

In harmony with these data, a significant increase of IL17A serum protein was observed in the untreated CCl4 group while a significant reduction was observed along the 6 weeks of BM-MSCs treatment (Fig 10a). Moreover, our results displayed a significant elevation of IL6 ($P < 0.05$) in serum of CCl4 group with a significant reduction ($P < 0.05$) in all treated groups (Fig 10c).

**BM-MSCs administration affects the expression of Stat5a gene and p-STAT5A**

In response to liver injury, the anti-fibrotic effect of Stat5 was demonstrated in various models of liver fibrosis [41]. Our results showed that mRNA of Stat5a was significantly upregulated ($P < 0.05$) by 6.06 folds in CCl4 group, but mRNA Stat5a was reduced by 1.72 folds after the 2nd week of treatment, significant downregulations ($P < 0.05$) were observed by 2.08 and 2.57 folds at 4th and 6th weeks, respectively (Fig 8b). Interesting data were obtained by the activated form of STAT5 protein, where a significant reduction of p-STAT5 protein ($P < 0.05$) was noticed in CCl4-induced group and significant elevation was observed by the 2nd week in response to BM-MSCs treatment (Fig 8d and 8e). CCl4 and recovery groups showed no significant difference ($P > 0.05$) in expression of p-STAT5 protein (Fig 8g). An early investigation described the lack of IL2 or disruption of its signaling through deletion of Stat5 resulted in enhanced Th17 cell differentiation [42]. Here, our CCl4 group showed a significant elevation of IL2 protein ($P < 0.05$) in serum and a significant reduction ($P < 0.05$) in response to BM-MSCs administration (Fig 10b).
Discussion

Recent studies illustrated the crucial role that IL17A plays in the development and progression of hepatic fibrosis [14], along with the anti-fibrotic activity of BM-MSCs [12, 43]. In this study, we demonstrated a therapeutic potential of BM-MSCs in CCl₄-induced rat liver fibrosis through inhibition of IL17A/F isoforms expressed genes and IL17 associated signaling pathway.

The current study represents the first report that highlights the inhibitory effect of BM-MSCs on IL6/STAT3 pathway in liver fibrosis. Previous studies have discussed the correlation between MSCs and IL6 in the progression of cancer [40, 44]. One study reported the secretion of IL6 by the BM-MSCs which activated IL6/Stat3 pathway promoting the invasion...
of the hepatocellular carcinoma cell line [30]. A recent study investigated the role of MSCs at different stages of hepatocellular carcinoma as well as liver fibrosis in rats [44]. In that study, the early stages of hepatocellular carcinoma showed the ability of MSCs to suppress liver cancer and reduce liver fibrosis and to employ anti-inflammatory effect via IL6 inhibition. On the other hand, MSCs promoted cancer in progressive stages due to the elevation of

![Figure 9](https://doi.org/10.1371/journal.pone.0206130.g009)

**Fig 9.** Protein expression of p-SMAD3 and TGFβR2. **a.** p-SMAD3 and **b.** TGFβR2 protein analysis, representative data of western blot are shown as mean ± SD in different groups (n = 3). **c.** Expression of p-SMAD3 and TGFβR2 proteins by western blot (WB) in liver tissues. Quantitative expression analysis of d. p-SMAD3. e. TGFβR2 in 1. Recovery group (R-6W), 2. Normal control, 3. Oil control, 4. CCl4 groups, 5. CCl4+BM-MSCs/2 weeks, 6. CCl4+ BM-MSCs/4 weeks, 7. CCl4+MSCs/6 weeks.

![Figure 10](https://doi.org/10.1371/journal.pone.0206130.g010)

**Fig 10.** IL17A, IL6 and IL2 protein expression levels in serum measured by ELISA. The data shown in (a), (b) and (c) are presented as the mean ± SD *P < 0.05, #P < 0.05 compared to control groups.
proinflammatory cytokines (IFN$\gamma$, TNF$\alpha$, IL6 and IL1$\beta$) expression in the tumor microenvironment [44]. These results indicate that the role of BM-MSCs could be perplexing according to the surrounding microenvironment.

In the present study, in parallel to the improvement of the histopathological structure of liver tissue confirming the therapeutic effect of BM-MSCs, the liver biomarkers ALT, AST, and ALP levels in the blood were significantly recovered and the fibrogenic Col1a1 mRNA were gradually decreased in the treated group and reached normal levels after 6 weeks of BM-MSCs implantation. These results agree with the previous studies reporting the ability of BM-MSCs to repair CCL$_4$-damaged liver by reduction of inflammation, collagen deposition, and remodeling [11, 12, 45]. The protective function of MSCs in liver fibrosis as well as liver inflammation could be explained by the modulatory effect of MSCs via paracrine mechanisms on reducing the function of activated hepatic stellate cells (HSCs) through secretion of IL-10. In addition, MSCs promote apoptosis of HSCs via hepatocyte growth factor (HGF) [46].

Upon BM-MSCs treatment, the mRNA levels of the unique hepatocyte marker Alb increased, while the Afp mRNA level decreased in a time dependent manner and these results agree with a previous study that correlated these changes in expression to the differentiation of BM-MSCs into hepatocyte-like cells and normalization of Alb could possibly need more time [47].

IL17 signaling contributes to the pathogenesis of liver fibrosis [16]. We evaluated the effect of BM-MSCs administration to CCL$_4$-induced liver fibrosis group on the expression of il17a/f isoforms and their receptors’ (Il17a and Il17r) genes. Here, upregulation of the expressed Il17a, Il17f, Il17ra and Il17rc were detected as previously reported [48]. Consequent to BM-MSCs administration, all genes were almost normalized after 6 weeks. Also, we reported elevation of IL17A and IL17RA proteins in fibrotic liver tissue with their reduction in response to BM-MSCs treatment. This could be anticipated to the anti-inflammatory modulation of MSCs [49] and its role in reduction of Th17 cells in liver [50].

Hence, IL17 is associated with IL6 concentration [51, 52] and serum level of IL6 and IL17 evaluate the severity of liver fibrosis [53, 54]. To our knowledge, the effect of BM-MSCs on the downstream pathway IL6/STAT3 has not been previously discussed. In this study, the anti-inflammatory role of MSCs was suggested as our results revealed that the upregulated IL6 and IL17A serum proteins in the fibrosis model were downregulated gradually with the improvement of fibrosis after BM-MSCs administration which agrees with a previous report [55].

The role of STAT3 is controversial in mediating signaling of liver fibrosis [18, 26]. On the other hand, IL17A signaling activates STAT3 and is suggested to promote the development of liver fibrosis [13]. Here, we demonstrated that upregulations of Phosphorylated STAT3 and Stat3 gene expression in CCL$_4$ group were downregulated over time of BM-MSCs transplantation.

Furthermore, STAT3 signaling pathways are essential for IL6-dependent hepatic stellate cells activation [56]. Thus, we suggest that BM-MSCs ameliorate liver fibrosis via downregulation of IL17A dependent IL-6/STAT3 signaling pathway.

SMAD3 is a key of signal transduction pathways in liver fibrosis [22] and elevated STAT3 phosphorylation in fibrosis is combined with TGF$\beta$1 and SMAD3 activation [18, 57]. Otherwise, the increased p-SMAD3 and TGF$\beta$R2 expression has been reported in CCL$_4$-induced acute liver injury [58] and BM-MSCs led to the recovery of liver function via the TGF$\beta$1/SMAD signaling pathway [34]. Herein, we report the downregulation of p-SMAD3 and TGF$\beta$R2 after BM-MSCs administration in rats with liver fibrosis, suggesting the inhibitory effect of BM-MSCs on CCL$_4$-induced fibrosis probably by affecting TGF$\beta$/SMAD signaling pathways through reduction of TGF$\beta$R2 and phosphorylation of SMAD3.
The antifibrotic effect of STAT5 was demonstrated in murine models of liver fibrosis [59, 60]. Few studies discussed the effect of BM-MSCs on the STAT5 expression. Hence, the current study declared the elevated level of Stat5a gene expression in CCl₄-induced group with gradual reduction over time in response to BM-MSCs administration. In contrast, Phosphorylated Stat5a was downregulated in CCl₄ group and was augmented after BM-MSCs transplantation.

Even though expression of Stat3 and Stat5a mRNA postulated no variability in CCl₄ groups, but the activated form gave the answer towards fibrogenesis and treatment. This might be justified by the fact that TGFβ is crucial in the development of liver fibrosis, as previous data proposed that upon development of liver fibrosis, TGFβ traps STAT5 in hepatocytes and lead to the activation of STAT3 [61]. This might verify the role of BM-MSCs in reduction of TGFβ1 [62]. Consequently, the activated form of STAT5A increased as well as fibrosis decreased in response to treatment.

It is crucial to mention that the recovery group in our study did not show any amelioration of fibrogenesis or studied parameters after 6 weeks of recovery and our results are in accordance with previous studies [11, 43, 47, 63–66].

In conclusion, we have detected BM-MSCs in the recipient rats suggesting their role in ameliorating liver tissue damage through their immunoregulatory activities by suppressing the inflammatory genes IL17A/RA and downregulating the IL6/STAT3 pathway.

Acknowledgments

The study was conducted at the Genetics Laboratory, Department of Zoology, Faculty of Science, Cairo University, Giza, Egypt.

Author Contributions

Conceptualization: Shimaa Farouk, Salwa Sabet, Akmal A. El-Ghor.

Data curation: Shimaa Farouk, Salwa Sabet.

Formal analysis: Shimaa Farouk.

Funding acquisition: Salwa Sabet, Akmal A. El-Ghor.

Investigation: Shimaa Farouk, Salwa Sabet, Akmal A. El-Ghor.

Methodology: Shimaa Farouk, Salwa Sabet, Akmal A. El-Ghor.

Project administration: Salwa Sabet, Akmal A. El-Ghor.

Resources: Salwa Sabet, Akmal A. El-Ghor.

Supervision: Salwa Sabet, Fatma A. Abu Zahra, Akmal A. El-Ghor.

Validation: Salwa Sabet, Akmal A. El-Ghor.

Visualization: Salwa Sabet, Fatma A. Abu Zahra.

Writing – original draft: Shimaa Farouk.

Writing – review & editing: Shimaa Farouk, Salwa Sabet, Fatma A. Abu Zahra, Akmal A. El-Ghor.

References

1. Friedman S. Liver fibrosis: from bench to bedside. Journal of hepatology Supplement. 2003; 38(1): 38–53.
2. Friedman SL. Mechanisms of disease: Mechanisms of hepatic fibrosis and therapeutic implications. Nature Clinical Practice: Gastroenterology & Hepatology. 2004; 1(2):98–105. https://doi.org/10.1038/ncpgasthep0055 PMID: 16265071

3. Merion RM. Current status and future of liver transplantation. Semin Liver Dis. 2010; 30(4):411–21. Epub 10/19. https://doi.org/10.1056/10-0300-1267541 PMID: 20960380.

4. Kia R, Sison RLC, Heslop J, Kitteringham NR, Hanley N, Mills JS, et al. Stem cell-derived hepatocytes as a predictive model for drug-induced liver injury: are we there yet? British Journal of Clinical Pharmacology. 2013; 75(4):865–96. https://doi.org/10.1111/j.1365-2125.2012.04360.x PMID: 22703588

5. Al Ghrabawy NM, Affify RAAM, Duya N, El Sayed AA. Differentiation of Bone Marrow Derived Mesenchymal Stem Cells into Hepatocyte-like Cells. Indian Journal of Hematology and Blood Transfusion. 2016; 32(3):276–83. https://doi.org/10.1007/s12288-015-0581-7 PMID: 27429519

6. Kiss J, Urban S V, Dudics V, Vas V, Uher F. Mesenchymal stem cells and the immune system—Immunosuppression without drugs. Orvosi Hetilap. 2008; 149(8):339–46. https://doi.org/10.1556/OH.2008.28291 PMID: 22228987.

7. Puglisi MA, Tesori V, Lattanzi W, Piscaglia AC, Gasbarrini GB, D’Ugo DM, et al. Therapeutic implications of mesenchymal stem cells in liver injury. J Biomed Biotechnology. 2011; 2011:860578. Epub 12/20. https://doi.org/10.1155/2011/860578 PMID: 22228987.

8. Sharma RR, Pollock K, Hubel A, McKenna D. Mesenchymal stem cell or stromal cells: A review of clinical applications and manufacturing practices. Transfusion. 2014; 54(5):1418–37. https://doi.org/10.1111/trf.12421 PMID: 24898458

9. Lagasse E, Connors H, Al-Dhalimy M, Reitsma M, Dohse M, Osborne L, et al. Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nature Medicine. 2000; 6(11):1229–34. https://doi.org/10.1038/712421 PMID: 11062533

10. Fang B, Shi M, Liao L, Yang S, Liu Y, Zhao RC. Systemic infusion of FLK1+ mesenchymal stem cells ameliorate carbon tetrachloride-induced liver fibrosis in mice. Transplantation. 2004; 78(1):83–8. https://doi.org/10.1097/01.TP.0000128326.95294.14 PMID: 15257043

11. Ali G, Masoud M. Bone marrow cells ameliorate liver fibrosis and express albumin after transplantation in CCI 4 -induced fibrotic liver. Saudi Journal of Gastroenterology. 2012; 18(4):263-. https://doi.org/10.4049/jimmunol.1203013 PMID: 23842754

12. Tan Z, Qian X, Jiang R, Liu Q, Wang Y, Chen C, et al. IL-17A plays a critical role in the pathogenesis of liver fibrosis through hepatic stellate cell activation. J Immunol. 2013; 191(4):1835–44. https://doi.org/10.4049/jimmunol.1203013 PMID: 23842754

13. Zepeeda-Morales ASM, del Toro Arreola S, García-Benavides L, Bastidas-Ramirez BE, Fatutis-Morris M, Pereira-Suárez AL, et al. Liver fibrosis in bile duct-ligated rats correlates with increased hepatic IL-17 and TGF-β2 expression. Annals of Hepatology. 2016; 15(3):418–26. PMID: 27049496

14. Gaffen SL. Structure and signalling in the IL-17 receptor family. Nature Reviews Immunology. 2009; 9(8):556–67. https://doi.org/10.1038/nri2586 PMID: 19575028

15. Meng F, Wang K, Aoyama T, Grivennikov SI, Paik Y, Scholten D, et al. IL-17 signaling in inflammatory cells, Kupffer cells and Hepatic Stellate cells exacerbates liver fibrosis Fanl. Gastroenterology. 2012; 143(3):1–18.

16. Ogata H, Chinen T, Yoshida T, Kinjo I, Takeasu G, Shiraishi H, et al. Loss of SOCS3 in the liver promotes fibrosis by enhancing STAT3-mediated TGF-β1 production. Oncogene. 2006; 25(17):2520–30. https://doi.org/10.1038/sj.onc.1209281 PMID: 16474852

17. Xu MY, Hu JJ, Shen J, Wang ML, Zhang QQ, Qu Y, et al. Stat3 signaling activation crosslinking of TGF-β1 in hepatic stellate cell exacerbates liver injury and fibrosis. Biochimica et Biophysica Acta—Molecular Basis of Disease. 2014; 1842(11):2237–45. https://doi.org/10.1016/j.bbadis.2014.07.025 PMID: 25092172

18. Jiang JX, Mikami K, Venugopali S, Li Y, Török NJ. Apoptotic body engulfment by hepatic stellate cells promotes their survival by the JAK/STAT and Akt/NF-xB-dependent pathways. Journal of Hepatology. 2009; 51(1):139–48. https://doi.org/10.1016/j.jhep.2009.03.024 PMID: 19457567

19. Zhang W, Niu M, Yan K, Zhai X, Zhou Q, Zhang L, et al. Stat3 pathway correlates with the roles of leptin in mouse liver fibrosis and sterol regulatory element binding protein-1c expression of rat hepatic stellate cells. International Journal of Biochemistry and Cell Biology. 2013; 45(3):736–44. https://doi.org/10.1016/j.biocel.2012.12.019 PMID: 23295202
21. O'Reilly S, Ciechomska M, Cant R, Van Laar JM. Interleukin-6 (IL-6) trans signaling drives a STAT3-dependent pathway that leads to hyperactive transforming growth factor-?? (TGF-??) signaling promoting SMAD3 activation and fibrosis via gremlin protein. Journal of Biological Chemistry. 2014; 289(14): 9952–60. https://doi.org/10.1074/jbc.M113.458822 PMID: 24550394

22. Fabregat I, Moreno-Càceres J, Sánchez A, Dooley S, Dewidar B, Giannelli G, et al. TGF-β signalling and liver disease. FEBS Journal. 2016; 2219–32. https://doi.org/10.1111/febs.13665 PMID: 26807763

23. Seyhan H, Hamzavi J, Wiercinska E, Gressner AM, Mertens PR, Kopp J, et al. Liver fibrogenesis due to cholestasis is associated with increased Smad7 expression and Smad3 signaling. Journal of Cellular and Molecular Medicine. 2006; 10(4):922–32. https://doi.org/10.1111/j.1582-4934.2006.tb00535.x PMID: 17125595

24. Dooley S, Ten Dijke P. TGF-β in progression of liver disease. 2012. p. 245–56.

25. Wang H, Lafdl F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: A novel therapeutic target. 2011. p. 536–50.

26. Deng YR, Ma HD, Tsuneyama K, Yang W, Wang YH, Lu FT, et al. STAT3-mediated attenuation of CC44-induced mouse liver fibrosis bythe protein kinase inhibitor sorafenib. Journal of Autoimmunity. 2013; 46:25–34. https://doi.org/10.1016/j.jaut.2013.07.008 PMID: 23948302

27. Liu Y-C, Zou X-B, Chai Y-F, Yao Y-M. Macrophage Polarization in Inflammatory Diseases. International Journal of Biological Sciences. 2014; 10(5):520–9. https://doi.org/10.7150/ijbs.8879 PMID: 24910531

28. Liu W-h, Song F-q, Ren L-n, Guo W-q, Wang T, Feng Y-q, et al. The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases. Journal of Cellular and Molecular Medicine. 2015; 19(3):511–20. https://doi.org/10.1111/jcmm.12482 PMID: 25534251

29. Zhang XW, Mi S, Li Z, Zhou JC, Xie J, Hua F, et al. Antagonism of Interleukin-17A ameliorates experimental hepatic fibrosis by restoring the IL-10/STAT3-suppressed autophagy in hepatocytes. Oncotarget. 2017; 8(6):9922–34. https://doi.org/10.18632/oncotarget.14266 PMID: 28039485.

30. Mi F, Gong L. Secretion of interleukin-6 by bone marrow mesenchymal stem cells promotes metastasis in hepatocellular carcinoma. Bioci Rep. 2017; 37(4). https://doi.org/10.1042/bsr20170181 PMID: 28659496.

31. Soleimani M, Nadri S. A protocol for isolation and culture of mesenchymal stem cells from mouse bone marrow. Nature Protocols. 2009; 4(11):102–6. https://doi.org/10.1038/nprot.2008.221 PMID: 19131962

32. Wang G, Li Z, Li H, Li L, Li J, Yu C. Metabolic profile changes of CCl4-induced liver fibrosis and inhibitory effects of Jiaqi Ganxiang granule. Molecules. 2016; 21(6). https://doi.org/10.3390/molecules21060698 PMID: 27248993

33. Downie T. Theory and Practice of Histological Techniques Edited by J.D. Bancroft & A. Stevens, Churchill Livingstone, Edinburgh, 740 pages, £55.00. Histopathology. 1990; 17(4):386-. https://doi.org/10.1111/1365-2559.1990.tb00755.x

34. Jang YO, Kim MY, Cho MY, Baik SK, Cho YZ, Kwon SO. Effect of bone marrow-derived mesenchymal stem cells on hepatic fibrosis in a thioacetamide-induced cirrhotic rat model. BMC Gastroenterology. 2014; 14(1). https://doi.org/10.1186/s12876-014-0198-6 PMID: 25425284

35. Fallatah HI. Noninvasive Biomarkers of Liver Fibrosis: An Overview. Advances in Hepatology. 2014; 2014:15. https://doi.org/10.1155/2014/357287

36. Ozaki I, Motomura M, Setoguchi Y, Fujio N, Yamamoto K, Kariya T, et al. Albumin mRNA expression in human liver diseases and its correlation to serum albumin concentration. Gastroenterologia Japonica. 1991; 26(4):472–6. https://doi.org/10.1007/BF02788216 PMID: 1916156

37. Takahara Y, Takahashi M, Wagatsuma H, Yokoya F, Zhang Q-W, Yamaguchi M, et al. Gene expression profiles of hepatic cell-type specific marker genes in progression of liver fibrosis. World journal of gastroenterology: WJG. 2006; 12(40):6473–99. https://doi.org/10.3748/wjg.v12.i40.6473 PMID: 17072980

38. Zepeda-Morales S, Del Toro-Arreola S, Sánchez-Orozco L, Fafutis-Morris M, García-Benavides L, Pereira-Suárez AL, et al. P0092: IL-17 A and F isoforms and their receptors mediate liver damage in experimental cholestasis and the IL17 A/F heterodimer induces a profibrogenic profile in hepatic stellate cells in vitro. Journal of Hepatology. 62:S335. https://doi.org/10.1016/S0168-8278(15)30313-5

39. Gao B. Cytokines, STATs and liver disease. Cellular & molecular immunology. 2005; 2(2):92–100.

40. Tang LY, Heller M, Meng Z, Yu LR, Tang Y, Zhou M, et al. Transforming growth factor-β (TGF-β) directly activates the JAK1-STAT3 axis to induce hepatic fibrosis in coordination with the SMAD pathway. Journal of Biological Chemistry. 2017; 292(10):4302–12. https://doi.org/10.1074/jbc.M116.773085 PMID: 28154170

41. Kong X, Horiguchi N, Mori M, Gao B. Cytokines and STATs in Liver Fibrosis. Front Physiol. 2012; 3:69. Epub 04/03. https://doi.org/10.3389/fphys.2012.00069 PMID: 22493582.
Zhao L, Feng Z, Hu B, Chi X, Jiao S. Ex vivo-expanded bone marrow mesenchymal stem cells facilitate...

Zhang G-Z, Sun H-C, Zheng L-B, Guo J-B, Zhang X-L. In vivo hepatic differentiation potential of human...

Parekkadan B, van Poll D, Megeed Z, Kobayashi N, Tilles AW, Berthiaume F, et al. Immunomodulation...

Zong C, Zhang H, Yang X, Gao L, Hou J, Ye F, et al. The distinct roles of mesenchymal stem cells in the...

Ahmed SK, Mohamed SA, Khalaf G, Fikry H. Role of bone marrow mesenchymal stem cells in the...

Yasumi Y, Takikawa Y, Endo R, Suzuki K. Interleukin-17 as a new marker of severity of acute hepatic...

Zepeda-Morales S, Del Toro-Arreola S, Sánchez-Orozco L, Fafutis-Morris M, García-Benavides L, Perreira-Suárez AL, et al. P0092: IL-17 A and F isoforms and their receptors mediate liver damage in experimental cholestasis and the IL17 A/F heterodimer induces a profibrogenic profile in hepatic stellate cells in vitro. Journal of Hepatology. 2017; 62:8335–S. https://doi.org/10.1016/S0168-8278(17)30319-5

Ghanam S, Pène J, Torcy-Moquet G, Jorgensen C, Yssel H. Mesenchymal Stem Cells Inhibit Human Th17 Cell Differentiation and Function and Induce a T Regulatory Cell Phenotype. The Journal of Immunology. 2010; 185(1):302. https://doi.org/10.4049/jimmunol.0902007 PMID: 20511548

Milosavljevic N, Gazdic M, Simovic Markovic B, Arsenijevic A, Nurkovic J, Dolicanin Z, et al. Mesenchymal stem cells attenuate liver fibrosis by suppressing Th17 cells—an experimental study. Transplant international: official journal of the European Society for Organ Transplantation. 2017. https://doi.org/10.1111/tri.13033 PMID: 28805262

Zhou L, Ivanov II, Spolski R, Min R, Shenderov K, Egawa T, et al. IL-6 programs TH-17 cell differentiation by promoting sequential engagement of the IL-21 and IL-23 pathways. Nature Immunology. 2007; 8:967. https://www.nature.com/articles/nri1488#supplementary-information. PMID: 17581537

Hammad LN, Abdelraouf SM, Hassanein FS, Mohamed WA, Schaalna MF. Circulating IL-6, IL-17 and vitamin D in hepatocellular carcinoma: Potential biomarkers for a more favorable prognosis? Journal of Immunotoxicology. 2013; 10(4):380–6. https://doi.org/10.3109/1547691X.2012.758198 PMID: 23350952

Yasumi Y, Takkakaya Y, Endo R, Suzuki K. Interleukin-17 as a new marker of severity of acute hepatic injury. Hepatology Research. 2007; 37(4):248–54. PMID: 17397512

Zhang H, Bernuzzi F, Lleo A, Ma X, Invernizzi P. Therapeutic Potential of IL-17-Mediated Signaling Pathway in Autoimmune Liver Diseases. Mediators Inflamm. 2015; 2015:436450. Epub 06/04. https://doi.org/10.1155/2015/436450 PMID: 26146463.

Pinheiro D, Leiroş L, Dáu JBT, Stumbo AC, Thole AA, Cortez EAC, et al. Cytokines, hepatic cell profiling and cell interactions during bone marrow cell therapy for liver fibrosis in cholestatic mice. PLOS ONE. 2017; 12(11):e0187970–e. https://doi.org/10.1371/journal.pone.0187970 PMID: 29176797

Kagan P, Sultan M, Tachlytski I, Safran M, Ben-Ari Z. Both MAPK and STAT3 signal transduction pathways are necessary for IL-6-dependent hepatic stellate cells activation. PLoS ONE. 2017; 12(5). https://doi.org/10.1371/journal.pone.0176173 PMID: 28472150

Liu Y, Liu H, Meyer C, Li J, Nadalin S, Königsrainer A, et al. Transforming growth factor-β (TGF-β)-mediated connective tissue growth factor (CTGF) expression in hepatic stellate cells requires Stat3 signaling activation. Journal of Biological Chemistry. 2013; 288(42):30708–19. https://doi.org/10.1074/jbc.M113.478685 PMID: 24005672

Niu L, Cui X, Qi Y, Xie D, Wu Q, Chen X, et al. Involvement of TGF-β1/Smad3 Signaling in Carbon Tetrachloride-Induced Acute Liver Injury in Mice. PLoS One. 2016; 11(5):e0156090. Epub 05/25. https://doi.org/10.1371/journal.pone.0156090 PMID: 27224286.

Blaas L, Kornfeld JW, Schramek D, Musteanu M, Zollner G, Gumhold J, et al. Disruption of the growth hormone-signal transducer and activator of transcription 5-insulinlike growth factor 1 axis severely...
aggravates liver fibrosis in a mouse model of cholestasis. Hepatology. 2010; 51(4):1319–26. https://doi.org/10.1002/hep.23469 PMID: 20162728

60. Baik M, Yu JH, Hennighausen L. Growth hormone—STAT5 regulation of growth, hepatocellular carcinoma, and liver metabolism. Ann N Y Acad Sci. 2011; 1229:29–37. https://doi.org/10.1111/j.1749-6632.2011.06100.x PMID: 21793836

61. Hosui A, Kimura A, Yamaji D, Zhu B-m, Na R, Hennighausen L. Loss of STAT5 causes liver fibrosis and cancer development through increased TGF-β and STAT3 activation. The Journal of experimental medicine. 2009. https://doi.org/10.1084/jem.20080003 PMID: 19332876

62. Jang YO, Kim YJ, Baik SK, Kim MY, Eom YW, Cho MY, et al. Histological improvement following administration of autologous bone marrow-derived mesenchymal stem cells for alcoholic cirrhosis: a pilot study. Liver Int. 2014; 34(1):33–41. Epub 2013/06/19. https://doi.org/10.1111/liv.12218 PMID: 23782511.

63. Cho K-A, Woo S-Y, Seoh J-Y, Han H-S, Ryu K-H. Mesenchymal stem cells restore CCl4-induced liver injury by an antioxidative process. Cell Biology International. 2012; 36(12):1267–74. https://doi.org/10.1042/CBI20110634 PMID: 23035905

64. Yu J, Hao G, Wang D, Liu J, Dong X, Sun Y, et al. Therapeutic Effect and Location of GFP-Labeled Placental Mesenchymal Stem Cells on Hepatic Fibrosis in Rats. Stem Cells Int. 2017; 2017:1798260. Epub 04/12. https://doi.org/10.1155/2017/1798260 PMID: 28491093.

65. Wang M, Zhang Xin, Xiong Xi, Yang Z, Li P, Wang JIE, et al. Bone Marrow Mesenchymal Stem Cells Reverse Liver Damage in a Carbon Tetrachloride-induced Mouse Model of Chronic Liver Injury. In Vivo. 2016; 30(3):187–93. PMID: 27107074

66. Li D, Fan J, He X, Zhang X, Zhang Z, Zeng Z, et al. Therapeutic effect comparison of hepatocyte-like cells and bone marrow mesenchymal stem cells in acute liver failure of rats. International Journal of Clinical and Experimental Pathology. 2015; 8(1):11–24. PMID: 25755689